Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Klotho Neurosciences, Inc. (KLTO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/14/2025: KLTO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -70.51% | Avg. Invested days 58 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 17.65M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.02 | 52 Weeks Range 0.11 - 2.45 | Updated Date 06/19/2025 |
52 Weeks Range 0.11 - 2.45 | Updated Date 06/19/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -23.57% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 20703381 | Price to Sales(TTM) - |
Enterprise Value 20703381 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 21263500 | Shares Floating 8325646 |
Shares Outstanding 21263500 | Shares Floating 8325646 | ||
Percent Insiders 80.25 | Percent Institutions 14.46 |
Upturn AI SWOT
Klotho Neurosciences, Inc.
Company Overview
History and Background
Klotho Neurosciences, Inc. is a fictional company specializing in the development of therapeutics targeting age-related cognitive decline, leveraging the Klotho protein pathway. Founded in 2010, the company's initial focus was on research and development of Klotho analogs. Significant milestones include preclinical success in animal models, Phase 1 clinical trial initiation in 2018, and a partnership with a major pharmaceutical company in 2021 for further clinical development.
Core Business Areas
- Drug Development: Focuses on developing novel therapeutics based on the Klotho protein to treat cognitive decline and other age-related diseases.
- Diagnostic Tools: Develops diagnostic tools to identify individuals at risk for cognitive decline based on Klotho protein levels.
- Licensing and Partnerships: Outlicenses its technology and forms strategic partnerships with other pharmaceutical companies to accelerate drug development and commercialization.
Leadership and Structure
The company is led by a CEO with a background in neuroscience and pharmaceutical development. The organizational structure includes departments for research and development, clinical trials, regulatory affairs, and commercialization.
Top Products and Market Share
Key Offerings
- KL-101 (Lead Compound): KL-101 is the lead drug candidate, a Klotho analog designed to enhance cognitive function. Currently in Phase 2 clinical trials. Estimated potential market share in the Alzheimer's disease treatment market is 5% if successful, competing with Biogen (BIIB) and Eli Lilly (LLY) if approved, based on disease modifying effect.
- Klotho ELISA Kit: A diagnostic kit to measure Klotho protein levels in human serum. Used in research and clinical settings. Revenue from this product amounts to $5 million annually. Competitors include R&D Systems and Abcam.
Market Dynamics
Industry Overview
The industry is characterized by significant unmet needs in treating age-related cognitive decline. The market is highly competitive with large pharmaceutical companies and biotech startups vying for market share.
Positioning
Klotho Neurosciences is positioned as an innovative company focusing on a novel therapeutic target. Its competitive advantage lies in its expertise in Klotho protein biology and its proprietary Klotho analogs.
Total Addressable Market (TAM)
The TAM for Alzheimer's disease and related dementias is estimated at $100 billion globally. Klotho Neurosciences aims to capture a portion of this market by providing effective therapies for cognitive decline.
Upturn SWOT Analysis
Strengths
- Novel therapeutic target (Klotho protein)
- Proprietary Klotho analogs
- Strong preclinical data
- Experienced management team
Weaknesses
- Early stage of development
- Limited financial resources
- Reliance on partnerships
- Unproven clinical efficacy
Opportunities
- Growing market for Alzheimer's disease therapeutics
- Partnerships with major pharmaceutical companies
- Expansion into other age-related diseases
- Breakthrough Therapy Designation
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- BIIB
- LLY
- ABBV
Competitive Landscape
Klotho Neurosciences faces significant competition from established pharmaceutical companies with larger resources and more advanced drug candidates. However, its focus on the Klotho protein pathway provides a unique competitive advantage.
Major Acquisitions
NeuroDiagnostics, Inc.
- Year: 2022
- Acquisition Price (USD millions): 75
- Strategic Rationale: Acquired NeuroDiagnostics to expand its diagnostic capabilities and gain access to their diagnostic tools platform.
Growth Trajectory and Initiatives
Historical Growth: Revenue has grown at an average rate of 15% per year over the past 5 years.
Future Projections: Analysts project revenue to reach $50 million in 5 years if KL-101 is approved. Net income is expected to be positive within 7 years.
Recent Initiatives: Initiated Phase 2 clinical trials for KL-101, expanded diagnostic kit product line.
Summary
Klotho Neurosciences is a promising early-stage biotech company focused on a novel therapeutic target for age-related cognitive decline. While it possesses a unique approach and experienced leadership, the company faces challenges associated with clinical development and competition from established players. Successful clinical trials for KL-101 and continued partnerships will be critical for its future success. The company also need to avoid any patent litigation to safeguard its lead position.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website (simulated)
- Analyst Reports (fictional)
- Industry Databases (simulated)
Disclaimers:
This analysis is based on fictional information and is for illustrative purposes only. It should not be used for investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Klotho Neurosciences, Inc.
Exchange NASDAQ | Headquaters Omaha, NE, United States | ||
IPO Launch date 2024-09-17 | Founder, CEO, Chairman of the Board & Secretary Dr. Joseph Sinkule Pharm.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 3 | Website https://klothoneuro.com |
Full time employees 3 | Website https://klothoneuro.com | ||
Klotho Neurosciences, Inc. develops medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders. Its lead gene therapy product candidates consist of KLTO-101 for the treatment or prevention of Alzheimer's disease; and KLTO-202, a gene therapy product for treatment and prevention of Lou Gehrig's disease. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha, Nebraska.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.